Medal Winning Abstracts

Each abstract was assessed by reviewers using a 1-5 scale on the following 5 criteria: relevance, originality, quality, bias, and clarity. These are the same criteria used by JMCP to evaluate manuscripts. The abstract's mean score on the 5 criteria was used to award Platinum, Gold, Silver, or Bronze medals.

**PLATINUM**

Saurabh (Rob) Aggarwal, BS, MS, PhD; [U32] Comprehensive Review of Managed Care Formulary Access Trends for Top 100 Selling Drugs

James Gagnon, PharmD; [U55] A Medication Prior Authorization Pilot Program in Primary Care Practices Increases Efficiency and Patient Care Outcomes

Andrew Howe, PharmD, BA; [N02] An Analysis of Real-World Outcomes with FSH Versus FSH+hMG in IVF: Results from a Large U.S. Medical and Pharmacy Claims Database

Douglas Mager, MA; [U45] Impact of Plan Sponsor Cost Sharing on Utilization of Specialty Medications

Daniel Ng, PharmD, MBA; [N01] Impact of Overactive Bladder Step-Therapy Policies on Medication Utilization and Expenditures Among Treated Members

Julie Olson, DNP, MS, RN, CQIA, CBE; [U16] Implementation of CMS-Recommended MED Point of Sale Edit in a Medicare Part D Population

Hoa Pham, PharmD; [M04] Cost Sharing and Abandonment Rates of Anti-inflammatory Biologics: Potential Opportunity for Biosimilars

Aaron Smith-McLallen; [U19] A Randomized Clinical Trial of Medication Therapy Management in a Commercial Population

**GOLD**

Carrie Armstrong, PharmD, MBA; [I33] Occurrence of Gastrointestinal Bleed with Anticoagulant Use: A Comparison of Outcomes Between Apixaban and Rivaroxaban

Jennifer Baird, PharmD Candidate; [C09] Palbociclib Utilization and Costs Among 18 Million Insured Americans: Managed Care Pharmacy Opportunities

Kevin Bowen, MD, MBA; [I25] Cumulative Incidence and Incremental Claims Cost of Coronary Heart Disease Events in a Commercially Insured Cohort Stratified by Risk

Karen Carroll, PharmD; [K07] Evaluation and Surveillance of Patient Adherence to Sofosbuvir Regimens for the Treatment of Hepatitis C Within a PPO Health Plan

Zoe Clancy, PharmD; [L18] Long-term Efficacy in Apremilast: Results from the ESTEEM Trials

Bobby Clark, PhD, MSPharm, MHA, MS, MA; [U01] Patients Who Utilized Retail Healthcare Clinics Have Fewer Emergency Department Visits and Incur Lower Overall Healthcare Cost

Ankur Dashputre, MS; [G18] Cost-Effectiveness of Alemtuzumab Versus Subcutaneous Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

Steve Deitelzweig, MD; [I16] All-Cause and Bleeding-Related Hospitalizations in Non-valvular Atrial Fibrillation Patients Initiating Oral Anticoagulant Therapy

Victoria Erxleben, PharmD; [U21] Prevalence and Cost of Unsafe Opioid Use in a Medicare Advantage Population


Reethi Iyengar, PhD, MBA, MHM; [U09] Medication Adherence and Biometric Outcomes Among Patients with Diabetes and Dyslipidemia: Before and After Testing

Stephen Johnston; [M09] The Association Between Anti-cyclic Citrullinated Peptide/Rheumatoid Factor Positivity and Healthcare Costs Among Patients with Rheumatoid Arthritis

Russell Knoth, PhD; [R01] The Budget Impact of Adopting Netupitant/Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in a U.S. Health Plan

Alexander Miguel, PharmD, CGP; [U31] Examining Alternate Standardized Scripts to Improve Comprehensive Medication Review Participation Rate

Philip Mease, MD; [M07] Patient-Reported Outcomes in Psoriatic Arthritis Patients with Dactylitis and Enthesitis: Results from the Corrona Registry

Michael Migden, MD; [C04] Comorbidities, Healthcare Utilization, and Costs of Advanced Basal Cell Carcinoma Among Commercially Insured Patients


Indira Pulliadath, MBA, MS; [B07] Evaluating Outcomes with Sofosbuvir and Sofosbuvir Plus Ledipasvir Using an Integrated Data Approach

Teresa Roane, PharmD; [U18] The Impact of a Telephonic Outreach Program on Medication Adherence in Medicare Advantage Prescription Drug Plan Members

Derek Tang, PhD, BSPharm; [M10] Adherence to Quality Standards for Time to Initiation of Disease-Modifying Anti-rheumatic Drugs Among...
Medal Winning Abstracts (continued)

Robin Turpin, PhD; [M03] The Impact of Urate-Lowering Therapies on Cardiovascular Event Rates and Expenditure in Gout Patients with Pre-existing Cardiovascular and Chronic Kidney Disease
Kathleen Villa, MS; [U26] Newly Diagnosed Narcolepsy: Analysis of Comorbidities, Medication Use, Medical Resource Utilization and Healthcare Costs

Evgeniya Antonova, MS, PhD; [J01] Healthcare Resource Use and Costs Associated with Side Effects of High Oral Corticosteroid Use in Asthma: A Claims-Based Analysis
Kristin Brown-Gentry, MS; [F27] The Impact of Direct Outreach Programs on Provider-Prescribing Patterns Related to Medication Adherence of Antipsychotic Medications
Beilei Cai; [E01] HbA1c Reduction, Medication Adherence, Treatment Patterns, and Costs in Patients with Type 2 Diabetes Mellitus Initiating Second-Line Antihyperglycemic Therapy After Metformin Monotherapy
Gretchen Chiu, MS; [G01] An Investigation of the Prevalence of Alzheimer’s Disease, Diagnostic Screening Rates and Associated Healthcare Costs and Resource Utilization Among the Medicare Population
Ankur Dashputre, MS; [G17] Cost-Effectiveness of Peginterferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

Alaina DeKerlegand, BS; [K01] Utilization and Economic Impact of Prescription Esomeprazole Pre- and Post-availability of Over-the-Counter Nexium 24HR in a Clinically Integrated Network
Meg Franklin, PharmD, PhD; [B13] Estimating the Budget Impact of Daclatasvir for the Treatment of Chronic Hepatitis C Virus for Genotype 3 Patients in a U.S. Health Plan
Alexa Halburian, BS; [U23] Utilization of Preventative Osteoporosis Therapy in Members on Androgen Deprivation Therapy Using Pharmacy Claims Data

Kristin Hanson, PharmD; [M08] Patient Feedback and Satisfaction with the RAPID3 Pilot Program
Ann Hartry, PhD; [F09] Burden of Adverse Event Reports for Atypical Antipsychotics: An Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS)
Keith Hoffman, PhD; [U04] A Drug Safety Rating System Based on Post-marketing Costs Associated with Adverse Events and Poor Patient Outcomes
David Kern; [I05] Decreased Rates of Health Plan Disenrollment for Patients with Cardiovascular Disease
Dure Kim, PharmD; [D05] Systematic Review of Erythropoietin-Stimulating Agents and Iron Supplementation Usage in Anemia Management Post Implementation of the Prospective Payment System
Jonathan Kish, PhD, MPH; [C12] The Importance of Duration of Treatment and Therapy Discontinuation Rates in Third-Line Relapsed/Refractory Multiple Myeloma Patients Treated in U.S. Community Oncology Practices
Amy Law, PharmD; [O1] Economic Modeling of Cost Differences Associated with Use of Different Intrauterine Devices from a U.S. Payer Perspective
Sam Leo, PharmD; [I27] Description of Adherence, Switches, and Discontinuations Among Statin Users in a Regional Medicare Health Plan
Elisabeth Oehrlein; [U22] Meeting the Challenges of the Revised AMCP Format: Continuing Education on Comparative Effectiveness Research

Shreekant Parasuraman, PhD; [D01] Thromboembolic Events and Associated Costs in Hydroxyurea-Treated Patients with Polycythemia Vera
Michael Poison, MS, PharmD; [G06] Real-World Analysis to Assess the Difference in Long-term Medication Adherence and Persistence with Fingolimod Compared to Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis
Yuri Sanchez, PhD; [B06] The Distribution of Pharmacy, Medical, and Total Costs in Patients with HCV
Yuri Sanchez, PhD; [B11] The Healthcare Cost Burden of HCV-Infected Baby Boomers in the United States
Brad Schenkel, MS; [D06] Budget Impact Analysis of Ibrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia
Brendan Seto; [I23] The Relationship Between Pharmaceutical Manufacturer Funding and Prescribing Patterns for Anticoagulants in the United States
Melody Tran, PharmD; [J02] Predictors of Pharmacotherapy Management of COPD Exacerbations Post-hospitalization/ED Visit as Defined by HEDIS
Khang Tran-Tan, PharmD, MBA; [I03] Improving Medication Adherence in Chronic Conditions Using Advanced Analytics and Predictive Modelling
Stuart Turner, BPharm, MPH; [I14] Factors Associated with High Healthcare Costs Among Patients with Heart Failure
Songkai Yan, MS; [B01] Impact of Tier 6 in Medicare Part D on Zoster Vaccine Uptake Among Medicare Beneficiaries in a Managed Care Organization
Songkai Yan, MS; [Z01] Relationship Between Patient Copayments in Medicare Part D and Vaccination Claim Status for Herpes Zoster and Tdap
Medal Winning Abstracts (continued)

Jay Andrew Barcelon; [U30] Follow-up to a Newly Established Managed Care Course Designed to Increase Early Exposure to Managed Care in Pharmacy School

John Barron, PharmD; [B10] Effectiveness of Sofosbuvir Regimens for Hepatitis C in a Real-World Setting

Machaon Bonafede, PhD, MPH; [M11] Evaluation of Healthcare Cost Changes from Increased Compliance to Biologics in Patients with Rheumatoid Arthritis

Kimberly Brown, PharmD Candidate; [B15] Impact of Adherence to HIV/AIDS Antiretroviral Therapy and Utilization of Opportunistic Infection Prophylaxis

Briana Buckley, PharmD, MSPharm; [D02] Real-World Dosing and Patient Characteristics of rFIXFc in Hemophilia B Patients

Julian Casciano, BS; [J05] Development and Validation of an Asthma Severity Risk Tool

Abimbola Farinde, PharmD; [F25] Effects of Memantine and One-on-One Caregiver Contact on Antipsychotic Medication Prescribed to Elderly Veterans with Dementia

Sara Fernandez-Lopez; [C15] Assessment of Pharmacists’ Views on Biosimilar Naming Conventions

Feride Frech-Tamas, PhD, MPH; [G26] Treatment Initiation Timing and Healthcare Costs in Newly Diagnosed Patients with Fibromyalgia

Kristen Johnson, PhD, MPH; [G05] Adherence and Persistence to Oral MS Disease-Modifying Treatment in a Real-World Setting

Shellie Keast, PhD; [B03] Socio-Demographic and Clinical Correlates of Treated Versus Untreated Members with Hepatitis C in a State Medicaid Program

Shellie Keast, PhD; [F02] Assessment of Pharmacy and Medical Utilization and Expenditures After the Addition of Prescriber Limitations to a State Medicaid’s Patient Review and Restriction Program

Jonathan Kish, PhD, MPH; [C13] Modeling the Budget Impact of Panobinostat for the Treatment of Relapsed/Refractory Multiple Myeloma from the Perspective of a U.S. Health Plan

Daniel Lane, PharmD, PhD; [M02] Dosing Patterns, Healthcare Costs, and Provider Characteristics in Patients with Rheumatoid Arthritis Being Treated with Biologic Disease-Modifying Drugs

Janice Lopez, PharmD, MPH; [F14] Association Between Patterns of Long-Acting Injectable Antipsychotic Medication Use and All-Cause Hospitalizations Among Dual Medicare Medicaid Eligible Patients with Schizophrenia

R. Preston Mason; [E21] Analysis of Omega-3 Fatty Acid Dietary Supplements with Respect to Content: Are They Appropriate for Patients?

Kemper May, PharmD Candidate; [I32] A Budget Impact Analysis of Alirocumab in Heterozygous Familial Hypercholesterolemia Treatment

Philip Mease, MD; [M06] Patient-Reported Outcomes in Psoriatic Arthritis Patients by Extent of Body Surface Area Affected by Psoriasis: Results from the Corrona Registry

Terrence O’Shea, BSPharm, PharmD; [U54] Medication Therapy Management Comprehensive Medication Reviews for Residents in Long-term Care Facilities- 2014 Results

Gary Oderda, PharmD, MPH; [M17] Prevalence and Direct Costs of Opioid Abuse in Medicare Beneficiaries

Tony Okoro, PharmD; [C05] Epidemiology of Advanced Melanoma: A U.S. Administrative Claims Analysis

Anisha Patel, BS, MS; [U38] Dispensing Channel Used for Specialty Drugs and Associated Costs in Medicare Part D Population

Amy Phillips, PharmD; [G11] Cost-Effectiveness of 44 mcg Subcutaneous Interferon Beta-1a Versus 30 mcg Intramuscular Interferon Beta-1a Using Composite Multiple Sclerosis Clinical Endpoints

Shannon Reynolds, MSPH; [G02] Impact of Alzheimer’s Disease Medication on Caregiver Burden

Yuri Sanchez, PhD; [B05] The Cost of Specialty HCV Populations with Private or Public Insurance

Gary Schneider, ScD, MSPH; [I10] Incident Events Associated with Use of Prostacyclins for Pulmonary Arterial Hypertension

Catherine Starner, PharmD; [I31] Medication Therapy Management Comprehensive Medication Review Impact Assessment

Michael Taitel, PhD; [Z04] Improving Medication Adherence and Healthcare Outcomes Through a Retail Pharmacy Chain

Jeffrey Trocio, MPH; [I18] Comparison of Medical Costs Among Treatment-Naive Non-valvular Atrial Fibrillation Medicare Advantage Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

Ozgur Tunceli, PhD; [C03] Economic Characteristics of Patients Initiating Chemotherapy in a Novel Cancer Care Quality Program

Fulton Velez, MD, MS, MBA; [G19] Role of Seizure Frequency and Severity in the Comparison of Economic Outcomes Associated with Monotherapy and Adjunctive Therapy Among Patients with Epilepsy

Yiqiong Xie, PhD, MPH; [E15] Is Lower Cost Share Related to a Higher Likelihood of Continued Home Glucose Testing?